Core Viewpoint - Lexicon Pharmaceuticals has successfully closed a public offering of 32 million shares of common stock and a concurrent private placement of 22.4 million shares of common stock and 367,145 shares of Series B Convertible Preferred Stock, with the offerings closing on February 2, 2026 [1]. Group 1: Offering Details - The public offering price for the common stock was set at $1.30 per share, while the Series B Convertible Preferred Stock was sold at $65 per share [1]. - An additional 30-day option has been granted to underwriters to purchase up to 4.8 million shares of common stock at the public offering price [2]. - The Private Placement Purchaser has the option to buy an additional 94,855 shares of Series B Convertible Preferred Stock, convertible into 4,742,744 shares of common stock, at the same price of $65 per share [2]. Group 2: Use of Proceeds - Lexicon intends to utilize the net proceeds from the offerings for the continued research and development of its drug candidates, as well as for working capital and other general corporate purposes [4]. Group 3: Regulatory Information - A shelf registration statement related to the public offering was filed with the SEC on August 2, 2024, and was declared effective on August 15, 2024 [5]. - The shares issued in the private placement have not been registered under the Securities Act and may not be offered or sold in the U.S. without proper registration or exemption [5]. Group 4: Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing medicines that transform patients' lives, with a pipeline targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolism, and other indications [7].

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy according to analysts. On January 14, Citi analyst Yigal Nochomovitz increased the price target for Lexicon to $2.10 from $1.90 while maintaining a Buy rating. This upward revision resulted from an updated financial model that accounted for upcoming milestones under the LX9851 partnership with Novo Nordisk. In Q3 2025, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) reported revenue of $14.2 million, which was drive ...

THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be $41.6 ...

On January 14, Lale Akoner, global market analyst at eToro, appeared on CNBC to state that 2026 is driven by rotation into small caps and advised diversification. Recent data from BofA showed that customers had been selling equities over the six weeks leading up to that point, alongside observed outflows from ETFs that had previously seen consistent inflows. Akoner interpreted this not as a broad move away from risk assets, but rather as a significant rotation within the risk asset class. The shift is drive ...

Financial Position - The company ended 2025 with cash, investments, and restricted cash totaling $125.2 million, sufficient to support operations into 2027[4]. Licensing and Milestones - The company achieved a $10 million milestone in January 2026 under its licensing agreement with Novo Nordisk, with potential for an additional $20 million in milestone payments throughout 2026[4]. Clinical Trials and Development - The SONATA-HCM pivotal Phase 3 study for sotagliflozin is targeting enrollment of 500 patients, with expected completion in mid-2026 and topline results anticipated in Q1 2027[9]. - The FDA has raised no objections to advancing pilavapadin into Phase 3 development for diabetic peripheral neuropathic pain (DPNP)[10]. - Pilavapadin has shown clinically meaningful efficacy with a two-point average daily pain score reduction from baseline at 12 weeks[11]. - The company is preparing to potentially resubmit the NDA for ZYNQUISTA® (sotagliflozin) in type 1 diabetes in 2026, pending safety data from the STENO1 study[13]. Stock Offering - The company announced a public offering of its common stock and a concurrent private placement to its largest stockholder, Invus, L.P.[5].

Core Viewpoint - Lexicon Pharmaceuticals, Inc. has initiated an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option for additional shares, subject to market conditions [1][2] Group 1: Offering Details - The public offering will include shares of common stock with a par value of $0.001, and the actual size and terms of the offering are not guaranteed [1] - Jefferies and Piper Sandler are serving as joint book-running managers for the offering [2] - Concurrently, Lexicon plans to conduct a private placement of common stock to Invus, L.P., its largest stockholder, which will not be registered under the Securities Act [3] Group 2: Use of Proceeds - Lexicon intends to utilize the net proceeds from the offering primarily for the research and development of its drug candidates, as well as for working capital and general corporate purposes [4] Group 3: Regulatory Information - A shelf registration statement related to the offering was filed with the SEC on August 2, 2024, and was declared effective on August 15, 2024 [5]

Core Viewpoint - Lexicon Pharmaceuticals is celebrating its 30th anniversary as a biopharmaceutical company and will ring the Nasdaq Stock Market Closing Bell on January 27, 2026, highlighting its commitment to developing therapies for serious cardiometabolic diseases and chronic neuropathic pain [1][2]. Company Overview - Lexicon Pharmaceuticals focuses on pioneering medicines that transform patients' lives, leveraging a strong scientific foundation in genomics to support its drug pipeline [2][3]. - The company has developed a unique genomics target discovery platform, Genome5000™, which has studied nearly 5,000 genes and identified over 100 protein targets with significant therapeutic potential [3]. Pipeline and Development - Lexicon has a promising pipeline of drug candidates in various stages of discovery and development, targeting conditions such as neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, and metabolism [3].

Group 1 - The article discusses Lexicon Pharmaceuticals, Inc. (LXRX) and its recent developments, particularly focusing on the advisory panel's split vote regarding the company's drug [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis of pharmaceutical companies through the Biotech Analysis Central service [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide specific financial data or performance metrics related to Lexicon Pharmaceuticals or the biotech industry [1][3][4]

Core Insights - Lexicon Pharmaceuticals has successfully completed the End-of-Phase 2 meeting with the FDA for pilavapadin, which is advancing into Phase 3 development for diabetic peripheral neuropathic pain (DPNP) [1][2] - The FDA raised no objections to the Phase 3 program, which will include two placebo-controlled studies comparing a 10 mg daily dose of pilavapadin to placebo [1][2] Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to study nearly 5,000 genes and identify over 100 protein targets with therapeutic potential [4] - The company has a pipeline of drug candidates in various stages of development, targeting conditions such as neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, and metabolism [4] Product Information - Pilavapadin is a once-daily, orally delivered small molecule inhibitor of AAK1, designed to treat neuropathic pain without affecting opiate pathways [3] - Preclinical studies have shown that pilavapadin penetrates the central nervous system and reduces pain behavior in neuropathic pain models [3]

Company Overview - Lexicon Pharmaceuticals was founded 30 years ago with the ambitious goal of creating knockout mouse lines for 5,000 genes to study their impacts [3] - The company has conducted over 80 clinical trials, leading to the approval of 2 medicines in the United States [4] Product Development - Lexicon has successfully commercialized INPEFA and developed a non-opioid treatment for neuropathic pain, as well as a new non-incretin mechanism for obesity [4]